Aoxing Pharmaceutical Company, Inc.
AOXG · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $2 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $2 | $0 | $1 |
| Operating Income | -$6 | -$2 | -$0 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $63 | $0 | $0 | $0 |
| Pre-Tax Income | $57 | -$2 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $57 | -$2 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EPS | 0 | -0 | -0 | -0 |
| % Growth | 2,199.7% | -306.3% | 60.7% | – |
| EPS Diluted | 0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 381,209 | 341,209 | 341,209 | 341,209 |
| Weighted Avg Shares Out Dil | 381,209 | 341,209 | 341,209 | 341,209 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $44 | -$40 |
| EBITDA | $57 | -$2 | $43 | -$1 |
| % Margin | – | – | – | – |